DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 211 filers reported holding DENALI THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 4.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,964,813 | -31.4% | 289,133 | -1.9% | 0.04% | -27.1% |
| Q2 2023 | $8,699,282 | +24.6% | 294,791 | -2.7% | 0.05% | +17.1% |
| Q1 2023 | $6,980,000 | -23.2% | 302,961 | -7.9% | 0.04% | -26.8% |
| Q4 2022 | $9,092,000 | +16.0% | 329,084 | +28.8% | 0.06% | +9.8% |
| Q3 2022 | $7,840,000 | +1.0% | 255,460 | -3.1% | 0.05% | +4.1% |
| Q2 2022 | $7,760,000 | +18.3% | 263,704 | +29.4% | 0.05% | +44.1% |
| Q1 2022 | $6,557,000 | -24.0% | 203,850 | +6.4% | 0.03% | -10.5% |
| Q4 2021 | $8,627,000 | -29.5% | 191,516 | -21.0% | 0.04% | -30.9% |
| Q3 2021 | $12,236,000 | -46.4% | 242,545 | -16.7% | 0.06% | -43.9% |
| Q2 2021 | $22,834,000 | +28.4% | 291,103 | -8.4% | 0.10% | +24.1% |
| Q1 2021 | $17,778,000 | -29.1% | 317,862 | +6.2% | 0.08% | -44.0% |
| Q4 2020 | $25,059,000 | – | 299,186 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
| Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
| Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
| Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
| MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
| Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
| PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
| HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |